Advances in the management of achondroplasia
Crossref DOI link: https://doi.org/10.1038/s41574-024-00994-w
Published Online: 2024-05-13
Published Print: 2024-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Savarirayan, Ravi http://orcid.org/0000-0002-5105-8427
Text and Data Mining valid from 2024-05-13
Version of Record valid from 2024-05-13
Article History
First Online: 13 May 2024
Competing interests
: R.S. has received honoraria from BioMarin, QED pharma, Ascendis and Sanofi.